Iovance Biotherapeutics to Present at Upcoming Conferences
06 sept. 2022 16h01 HE
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today...
Iovance Biotherapeutics to Present Posters at ESMO 2022
06 sept. 2022 09h00 HE
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today...
Iovance Biotherapeutics Initiates Biologics License Application (BLA) Submission for Lifileucel in Advanced Melanoma
25 août 2022 07h30 HE
|
Iovance Biotherapeutics, Inc.
First TIL Therapy BLA Submission Initiated with U.S. Food and Drug Administration Complete BLA Submission on Track for Fourth Quarter 2022 SAN CARLOS, Calif., Aug. 25, 2022 (GLOBE NEWSWIRE) --...
Iovance Biotherapeutics Reports Second Quarter and First Half 2022 Financial Results and Corporate Updates
04 août 2022 16h01 HE
|
Iovance Biotherapeutics, Inc.
First Biologics License Application (BLA) Submission on Track in August 2022 SAN CARLOS, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage...
Iovance Biotherapeutics to Host Second Quarter Financial Results Conference Call and Webcast on Thursday, August 4, 2022
27 juil. 2022 07h00 HE
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will...
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
22 juil. 2022 17h15 HE
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., July 22, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today...
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
17 juin 2022 17h15 HE
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., June 17, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today...
Iovance Biotherapeutics Appoints Wendy L. Dixon, Ph.D., to Board of Directors
13 juin 2022 16h01 HE
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., June 13, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor...
Iovance Biotherapeutics to Present at Upcoming Conferences
08 juin 2022 16h01 HE
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today...
Iovance Biotherapeutics Announces Positive Clinical Data for Lifileucel in Advanced Melanoma
26 mai 2022 16h01 HE
|
Iovance Biotherapeutics, Inc.
Positive Results in Advanced Melanoma Patients, Including a 29% Objective Response Rate (ORR) in Cohort 4 of the C-144-01 Study Biologics License Application (BLA) Submission Planned for August 2022 ...